Medicus pharma ltd. provides update on united arab emirates (uae) sknjct-004 phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (bcc)

Cleveland clinic abu dhabi (ccad) has commenced recruitment in this 36 participant study philadelphia, pennsylvania / access newswire / september 8, 2025 / medicus pharma ltd. (nasdaq:mdcx) ("medicus" or the "company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that the sknjct-004 phase 2 clinical study, to non-invasively treat bcc of the skin, has commenced patient recruitment in cleveland clinic abu dhabi (ccad).
BCC Ratings Summary
BCC Quant Ranking